Holen Sie sich die Stockscreener-App
1.27
2.42%
0.03
Schlusskurs vom Vortag:
$1.24
Offen:
$1.26
24-Stunden-Volumen:
3.79M
Relative Volume:
0.48
Marktkapitalisierung:
$381.47M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.8467
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-3.05%
1M Leistung:
-10.56%
6M Leistung:
-5.22%
1J Leistung:
-9.29%
1-Tages-Spanne:
$1.22
$1.28
1-Wochen-Bereich:
$1.20
$1.328
52-Wochen-Spanne:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.27 | 372.46M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.94 | 231.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.22 | 158.98B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
392.31 | 150.76B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.90 | 119.10B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.94 | 47.53B | 5.69B | 1.41B | 577.90M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Will Pacific Biosciences of California Inc. bounce back from current supportMarket Risk Summary & Stepwise Trade Execution Plans - Newser
Quantitative breakdown of Pacific Biosciences of California Inc. recent moveEarnings Miss & Real-Time Sentiment Analysis - Newser
What’s the profit margin of Pacific Biosciences of California Inc.Price Action & Expert-Curated Trade Recommendations - خودرو بانک
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq - sharewise.com
Will a bounce in Pacific Biosciences of California Inc. offer an exitJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Visual analytics tools that track Pacific Biosciences of California Inc. performancePortfolio Risk Report & Weekly High Potential Alerts - Newser
What MACD and RSI say about Pacific Biosciences of California Inc.2025 Big Picture & Short-Term High Return Strategies - Newser
Powered by PacBio: Selected publications from August 2025 - PacBio
Pacific Biosciences shares rise 1.35% premarket after partnering with EpiCypher for novel insights in chromatin biology. - AInvest
Will Pacific Biosciences of California Inc. benefit from seasonality2025 Geopolitical Influence & Proven Capital Preservation Tips - خودرو بانک
Is Pacific Biosciences of California Inc. stock bottoming outJuly 2025 Final Week & Real-Time Stock Price Movement Reports - Newser
Will Pacific Biosciences of California Inc. benefit from macro trendsWeekly Trade Report & Community Shared Stock Ideas - Newser
Volatility clustering patterns for Pacific Biosciences of California Inc.CEO Change & Short-Term High Return Ideas - Newser
What is Pacific Biosciences of California Inc. s P E ratio telling usJuly 2025 Technicals & Fast Entry and Exit Trade Plans - خودرو بانک
Signal strength of Pacific Biosciences of California Inc. stock in tech scannersQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - Newser
PacBio and EpiCypher partner on chromatin analysis technology - Investing.com
PacBio and EpiCypher Collaborate to Enhance Fiber-seq Assays with CUTANA Hia5 Enzyme for Improved Insights into Chromatin Biology - Quiver Quantitative
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow - Yahoo Finance
Pacific Biosciences Of California, Inc. shares rise 1.56% premarket after FDA approved breakthrough therapies for aggressive malignancies. - AInvest
How to escape a deep drawdown in Pacific Biosciences of California Inc.Buy Signal & Growth Oriented Trade Recommendations - Newser
Is Pacific Biosciences of California Inc. trending in predictive chart modelsWeekly Trading Summary & High Accuracy Trade Alerts - Newser
Is Pacific Biosciences of California Inc. a defensive stockWeekly Profit Summary & Weekly Market Pulse Alerts - خودرو بانک
Does Pacific Biosciences of California Inc. have pricing powerTrade Entry Summary & Community Consensus Picks - خودرو بانک
Relative strength of Pacific Biosciences of California Inc. in sector analysisPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
Is Pacific Biosciences of California Inc. affected by consumer sentimentWeekly Gains Report & Stock Timing and Entry Methods - خودرو بانک
Market Trends: Is Pacific Biosciences of California Inc. a defensive stockPortfolio Performance Summary & Real-Time Volume Triggers - خودرو بانک
Can Pacific Biosciences of California Inc. hit a new high this monthMarket Trend Report & Growth Focused Entry Reports - Newser
Published on: 2025-09-02 10:17:32 - Newser
Is Pacific Biosciences of California Inc. stock a good pick for beginners2025 Price Action Summary & Verified Swing Trading Watchlists - خودرو بانک
What high frequency data says about Pacific Biosciences of California Inc.Dividend Hike & Weekly Breakout Watchlists - Newser
Street Watch: What’s next for Pacific Biosciences of California Inc. stockMarket Movement Recap & Weekly Consistent Profit Watchlists - خودرو بانک
What drives Pacific Biosciences of California Inc.’s stock priceLayoff News & Expert-Curated Trade Recommendations - خودرو بانک
Chart Patterns Forming a Bullish Setup in Pacific Biosciences of California Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Can momentum traders help lift Pacific Biosciences of California Inc.July 2025 Catalysts & Safe Capital Investment Plans - Newser
Should you hold or exit Pacific Biosciences of California Inc. nowJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
Using Ichimoku Cloud for Pacific Biosciences of California Inc. technicalsJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - Newser
What makes Pacific Biosciences of California Inc. stock price move sharplyInflation Watch & Safe Entry Point Identification - Newser
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):